This inventor holds 3 USPTO granted patents. Top assignees: Pharmacia Genetic Engineering, Inc., Other. Active years: 1993-2004.
Location History:
- La Jolla, CA (US) (1993 - 1995)
- San Francisco, CA (US) (2004)
Company Filing History:
2 out of 2 
1 out of 834,350 Years Active: 1993-2004
Title: The Innovations of Torsten B Helting
Introduction
Torsten B Helting is a notable inventor based in La Jolla, CA (US). He has made significant contributions to the field of genetic engineering, particularly in the development of recombinant viral antigens. With a total of 3 patents, his work has advanced diagnostic methods and therapeutic approaches for viral infections.
Latest Patents
Helting's latest patents include innovative methods and systems for producing recombinant viral antigens. One of his key inventions relates to recombinant expression vectors that express segments of deoxyribonucleic acid encoding recombinant HIV and HCV antigens. These vectors are transformed into host cells, allowing for the expression of large quantities of these antigens. Additionally, he has developed compositions containing isolated antigens, diagnostic systems utilizing these antigens, and methods for assaying body fluids to detect antibodies against the antigens. Another significant patent involves HIV antibody assays comprising p24-gp41 chimeric antigens. This invention includes a DNA segment encoding a recombinant HIV p24 protein or HIV p24-gp41 fusion protein, along with a recombinant DNA molecule capable of expressing either protein. The methods for producing the fusion protein and the diagnostic systems using this protein are also described in his patent.
Career Highlights
Throughout his career, Torsten B Helting has worked with Pharmacia Genetic Engineering, Inc., where he contributed to groundbreaking research in genetic engineering. His expertise in recombinant technology has positioned him as a key figure in the development of diagnostic tools for viral infections.
Collaborations
Helting has collaborated with notable professionals in his field, including Michael F Nunn and Hakan Drevin. These collaborations have further enhanced his research and development efforts in the area of recombinant viral antigens.
Conclusion
Torsten B Helting's innovative work in the field of genetic engineering has led to significant advancements in the production of recombinant viral antigens. His contributions continue to impact the development of diagnostic methods and therapeutic strategies for viral infections.